Cellectis Presents Innovative Research on Gene Therapy Techniques
NEW YORK — Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a pioneer in the biotechnology field, is set to present new insights into their groundbreaking gene-editing platform at an upcoming congress. This clinical-stage company specializes in creating life-saving therapies that leverage their advanced gene-editing technologies. At the prestigious European Society of Cell and Gene Therapy's annual congress, Cellectis will showcase pre-clinical data shedding light on their novel TALE base editors (TALEB) and a method for enhancing non-viral gene insertion. This event promises to mark a significant moment in gene therapy.
Details of the Presentations
Cellectis will highlight their findings through two key presentations, each focusing on different innovative approaches to gene editing:
Controlling C-to-T Editing with TALE Base Editors
In this session, Alexandre Juillerat, Ph.D., Vice-President of Gene Editing at Cellectis, will present vital research findings:
- TALE base editors (TALEB) are advanced tools designed to facilitate precise DNA editing, specifically converting cytosine (C) to thymine (T) using a method that involves creating an uracil intermediate.
- Recently developed strategies by Cellectis provide a comprehensive method for assessing how different compositions influence the efficiency of edits within a specific genomic region.
- This research delivers significant insights into the efficacy of TALEB and opens doors for potential therapeutic applications.
Efficient Gene Insertion Using Circular Single-Stranded DNA
Julien Valton, Ph.D., Vice-President of Gene Therapy at Cellectis, will lead this session:
- Emerging non-viral techniques such as circular single-stranded DNA (CssDNA) show promise as efficient delivery methods for gene therapy applications.
- Cellectis has innovated a process that merges their TALEN technology with non-viral carriers to improve gene insertion rates into hematopoietic stem and progenitor cells (HSPCs).
- This approach aims to enhance gene therapy’s efficacy, particularly in utilizing long-term hematopoietic stem cells, which are crucial for cellular therapies.
About Cellectis and Their Vision
Cellectis has made substantial contributions within the biotechnology industry via their pioneering gene-editing technology, TALEN. Their unique allogeneic approach to CAR-T immunotherapies has led to the development of off-the-shelf, ready-to-use cell therapies aimed at treating patients with various forms of cancer. With 25 years of experience, Cellectis continues to drive innovation, focusing on unmet medical needs across multiple diseases.
The company's main office is located in Paris, France, and they also operate facilities in New York and Raleigh. As listed entities on the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS), Cellectis remains committed to enhancing the science of gene editing.
For more information about Cellectis and their groundbreaking work in gene therapy, you can visit their official website.
Frequently Asked Questions
What is Cellectis known for?
Cellectis is recognized for its pioneering gene-editing platform focused on developing cell and gene therapies for cancer and other diseases.
What are TALE base editors?
TALE base editors are specialized gene-editing tools that allow researchers to make precise changes in DNA by converting specific bases.
What significance does the European Society of Cell and Gene Therapy have?
This society provides a platform for leading researchers and companies to share advancements in the rapidly evolving field of gene therapy.
How does Cellectis enhance gene therapy?
Cellectis integrates non-viral techniques and TALEN technology to improve gene insertion and overall efficacy in therapeutic applications.
Where can I find more information about Cellectis?
For additional insights into their research and developments, you can visit the Cellectis official website.
